Ocugen has reported preliminary phase 2 data on its eye disease gene therapy, providing more evidence that the candidate may ...

Companies across the globe are diligently working toward developing novel Dry Age Macular Degeneration treatment therapies ...

Scientists at USC are launching a new trial to test a tiny stem cell implant that could restore vision in people with ...

In advanced dry disease, a key problem is failure of retinal pigment epithelium, often shortened to RPE. These cells help ...

“This study suggests that there is no protective (or harmful) association of memantine [a second-line drug for dementia] or donepezil [a first-line drug] with the risk of developing age-related ...

A clinical trial is typically the first look at how an experimental drug works in humans. Character Biosciences is entering the clinic with a trove of company-generated human data already in hand.

GLP-1 drugs are associated with a higher risk of “wet” age-related macular degeneration in people with type 2 diabetes, according to a new study. Researchers found that the risk substantially ...

Outlook Therapeutics received notice that the Food and Drug Administration can't approve its biologics license application for a drug designed to treat macular degeneration.

There is strong interest across many stakeholders to increase progress around developing treatments for dry age-related macular degeneration (AMD). Advancements in drug discovery and development in ...

One option for macular degeneration cuts treatment costs from $2,000 to $50. April 4, 2011— -- One drug costs $50 per dose. The other costs $2,000 per dose. Now, new research shows that the drug ...

In microseconds, every light ray that enters the eye triggers an explosion of coordinated cellular events. Entering light rays focus on a light-sensitive tissue at the back of the eye called the ...